Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.
Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.
With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.
Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.
Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.
Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.
Takeda showcases its late-stage pipeline featuring six programs with potential peak revenue of $10B-$20B. The company expects Phase 3 data readouts in 2025 for three key treatments: oveporexton (narcolepsy), zasocitinib (psoriasis), and rusfertide (polycythemia vera), with regulatory filings planned for FY2025-2026.
The pipeline includes additional promising treatments: mezagitamab for immune disorders, fazirsiran for liver disease, and elritercept for anemia in hematologic cancers. Five more regulatory filings are anticipated during FY2027-2029, demonstrating Takeda's commitment to sustainable growth through 2030 and beyond.
Takeda has entered into an exclusive licensing agreement with Keros Therapeutics for elritercept, a late-stage activin inhibitor designed to treat anemia in hematologic cancers. The agreement grants Takeda exclusive global rights outside mainland China, Hong Kong, and Macau. Elritercept targets myelodysplastic syndromes (MDS) and myelofibrosis (MF), and has received FDA Fast Track designation for MDS treatment. The drug has shown promising clinical activity in early studies. Takeda will pay $200 million upfront, plus potential milestone payments and royalties. Two Phase 2 trials are ongoing, with a Phase 3 RENEW trial for MDS patients starting soon.
Alloy Therapeutics and Takeda have announced a strategic collaboration and license agreement to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). The technology, developed through Takeda's T-CiRA joint research program with Kyoto University, aims to create 'off-the-shelf' cell therapies with enhanced potency and lower manufacturing costs compared to autologous cell therapy. Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Alloy will establish a Japanese subsidiary at Shonan Health Innovation Park to support these efforts.
Takeda reported strong H1 FY2024 results with revenue growth of +13.4% (AER) and +5.0% (CER), driven by Growth & Launch Products (+18.7% CER). Core Operating Profit increased by +12.9% CER with a margin of 30.2%. The company upgraded its FY2024 outlook due to stronger performance and milder VYVANSE generic erosion. Notable achievements include ENTYVIO's double-digit growth, ADZYNMA's EU approval, FRUZAQLA's Japan launch, and TAK-861's Phase 3 trial initiation for narcolepsy. The revised guidance projects flat to slightly increasing core revenue, with core operating profit showing a mid-single-digit decline.
Takeda and Boston Medical Center (BMC) announced a three-year collaboration to reduce greenhouse gas emissions in healthcare, focusing on regulated medical waste and pharmaceutical packaging. The initiative aims to identify and pilot decarbonization solutions that can be shared across the healthcare ecosystem. BMC will conduct waste audits in clinical areas to identify emission hotspots and test new technologies. This partnership supports Takeda's goal to achieve net-zero emissions in operations by 2035 and across its value chain by 2040, recently validated by the Science Based Targets initiative.
Ciconia Bioventures Inc., a joint venture company, has been established based on a master agreement signed by Takeda Pharmaceutical Company (TSE: 4502/NYSE: TAK), Astellas Pharma Inc. (TSE: 4503), and Sumitomo Mitsui Banking . The company aims to translate innovative technologies and drug discovery programs from Japan into clinical applications, focusing on:
- Covering the entire process from early drug discovery research to establishing biotech startups
- Formulating development strategies and enhancing the value of promising drug discovery seeds
- Integrating R&D funding and experienced management teams to launch new startups
- Collaborating with academia, biotech ventures, and pharmaceutical companies across Japan
Ciconia's goal is to advance innovative drug discovery programs, incubate globally competitive drug discovery technology, and foster entrepreneurship in Japan's pharmaceutical sector.
Tempus AI, Inc. (NASDAQ: TEM) announces an expanded collaboration with Takeda to enhance oncology research and development. The partnership leverages Tempus' de-identified multimodal datasets and biological modeling capabilities to advance Takeda's cancer therapeutics pipeline. Takeda researchers will use Tempus' analytics platform, Lens, to access de-identified patient records and AI-enabled tools.
The collaboration includes a multi-phase biological modeling project using one of the world's largest repositories of patient-derived tumor organoids. Tempus is working with Takeda on a panel of 60 organoids spanning 10 cancer indications to evaluate preclinical candidates. This approach aims to enhance drug effectiveness prediction and guide early candidate prioritization.
Initial work has already yielded research to be presented at an upcoming medical congress, demonstrating the potential of this data-first approach in accelerating insights for drug development.
Takeda (TSE:4502/NYSE:TAK) has received approval from the Japanese Ministry of Health, Labour and Welfare for FRUZAQLA (fruquintinib), a selective oral inhibitor of VEGFR-1, -2 and -3, to treat advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and has progressed after chemotherapy. The approval is based on the FRESCO-2 trial, a global Phase 3 study that met all primary and key secondary efficacy endpoints.
FRUZAQLA demonstrated consistent benefits regardless of previous therapies and showed a manageable safety profile. It is the first novel targeted therapy in Japan for metastatic CRC regardless of biomarker status in over a decade. The treatment offers new hope for patients with metastatic CRC, addressing the need for new options in a disease with low 5-year survival rates.
Takeda (TSE:4502/NYSE:TAK) will present additional data from Phase 2b trials and long-term extension study of TAK-861, an investigational oral orexin receptor 2 selective-agonist, for narcolepsy at Sleep Europe 2024. The presentations will highlight TAK-861's impact on daily functioning, cognition, and sleep quality in narcolepsy type 1 (NT1) and type 2 (NT2) patients. Based on positive Phase 2b results, Takeda has initiated the FirstLight Study, a global Phase 3 trial evaluating TAK-861 in adults with NT1. The drug aims to address the underlying pathophysiology of NT1 and could potentially become the first treatment to do so. Takeda is also developing assets for narcolepsy type 2 and idiopathic hypersomnia.
Takeda has committed JPY4.6 billion (approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners, aiming to improve health systems in low and middle-income countries. This initiative is expected to impact 27 million people across 93 countries by 2030. The new partnerships will focus on:
1. Expanding vaccine access through pharmacy-based immunization in Africa
2. Integrating community-driven healthcare in rural South Africa
3. Increasing care access for women and girls in conflict-affected areas
4. Building skilled health workforces in African countries
5. Strengthening national health systems for disease outbreak response
These partnerships were selected by over 22,000 Takeda employees worldwide, demonstrating the company's commitment to collaborative global corporate giving. Since 2016, Takeda's Global CSR Program has reached 17.8 million direct beneficiaries in 93 countries, contributing to various aspects of health system strengthening.
FAQ
What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What are Takeda Pharmaceutical's core therapeutic areas?
Where is Takeda Pharmaceutical headquartered?
What recent collaborations has Takeda Pharmaceutical entered into?
How diversified is Takeda's revenue geographically?
What was Takeda's revenue in fiscal 2023?
Who can benefit from Takeda's new drug NBI-1065845?
What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?
How long has Takeda been in the pharmaceutical industry?
In how many countries does Takeda operate?
How does Takeda contribute to the field of major depressive disorder treatment?
